Skip to main content

Notice

We are in the process of rolling out a soft launch of the RDA website, which includes a new member platform. Existing RDA members PLEASE REACTIVATE YOUR ACCOUNT using this link: https://rda-login.wicketcloud.com/users/confirmation. Visitors may encounter functionality issues with group pages, navigation, missing content, broken links, etc. As you explore the new site, please provide your feedback using the UserSnap tool on the bottom right corner of each page. Thank you for your understanding and support as we work through all issues as quickly as possible. Stay updated about upcoming features and functionalities: https://www.rd-alliance.org/rda-web-platform-upcoming-features-and-functionalities/

#129768

Dear Anne,
Thanks for the information.
When I was reading the minutes of last week’s call (unfortunately I could not attend) I saw that an EC call for proposals have been discussed. As the deadline to submit a proposal for this call is already June 11, so only one day after our next clinical subgroup meeting, I was wondering if there was a follow-up action in this group (or a subgroup of it), was there?
Best regards,
Martin
——————————————
Martin Golebiewski
HITS gGmbH
Schloss-Wolfsbrunnenweg 35
69118 Heidelberg
Germany
phone +49 6221 533 281
fax +49 6221 533 298
email ***@***.***-its.org
http://www.h-its.org
_________________________________________________
Amtsgericht Mannheim / HRB 337446
Managing Director: Dr. Gesa Schönberger
Scientific Director: PD Wolfgang Müller
Von: im Auftrag von cambonthomsen via RDA-COVID19-Clinical
Antworten an: “***@***.***-tlse3.fr
Datum: Mittwoch, 3. Juni 2020 um 12:44
An: “***@***.***-groups.org
Cc: “Lin, Dawei (NIH/NIAID) [E]” , Sergio Bonini , “Jackson-Dipina, Andrea (NIH/OD) [E]” , “***@***.***-duesseldorf.de
Betreff: [rda-covid19-clinical] Call today cancelled Clinical sub-group RDA COVID19- Information mail.
Dear all Co-moderators and members of the Clinical sub-group RDA COVID-19,
Due to difficulties of several co-moderators and the Co-Chair to be available today for the usual Clinical sub-group meeting we must cancel the today call; that of next week is maintained ; we are circulating instead a short update on “where we are” and “What still has to be done” and reminder of the webinar next week Tuesday 9 June at 11.00 am UTC
1. Congratulations to the 5th release and final draft. The future release (planned for 15 June, after incorporation of comments, open until 8 June) is considering to include supporting outputs (official designation of what was before called “longer document”) for the groups that have those. We had not planned to have such a document for our group. In case you have some reason to change this policy, please let moderators know. Please make comments or any remarks you may have regarding the 5th release through the “request for comments function” (wee below the mail that gives the link to access the documents of the 5th release (main document, executive summary, press release); it is particularly important you read the main document as many people have before read only their sub-group production and the part 2 (generic transversal aspects) have been extracted from the various sub-groups documents if they were general and transversal. We all will be endorsing the whole document.
2. Glossary and list of acronyms. The glossary has been preceded by a disclaimer sentence mentioning that it is for helping the reader but does not necessarily constitute a consensus definition (as proposed originally by Sergio Bonini); there are still possibility of improving definitions ; check if it is satisfactory or make proposals. You can mention that to moderators. Abbreviations and acronyms must correspond to those used by the institutions in question; you can also check.
3. Resources. It is still possible to add resources ; there is a provisional zotero file created for that, that will be merged with the existing cleaned persent file as per 5th release; If you have such additional resources (not already present), please let moderators know.
4. The decision tree group (now called “visualistion group”) is considering three approaches to make the full document easy to navigate. They are infographics, mindmap, and wizard. More information is at https://docs.google.com/document/d/1LJu2CVHBKUbuMIrSyztoSrM_mVZ-nKvrf2Zi….
5. There will be a webinar on June 9. Each subgroup will report its highlights. Please let the moderators know if you have any suggestions for the presentation.
6. The dissemination to institutions, networks, colleagues and variosu stakeholders is important at this stage, so pleasecontinue to do so; you can report your dissemination efforts to moderators or directly to Hilary : ***@***.***-foundation.org.
We hope this is useful for you and we hope to hear from you and “see” you at the webinar and at our next call; we thank you again for your participation in this work and are very grateful for all your efforts!
Co-Moderators: Sergio Bonini (***@***.***), Andrea Jackson-Dipina (***@***.***), Dawei Lin (***@***.***), Christian Ohmann ( ***@***.***-duesseldorf.de )
Co-Chair Liaison: Anne Cambon-Thomsen (***@***.***-tlse3.fr)
Below is the mail with access to the documents of the 5th release :
Dear COVID-19 Working Group Members,
We have just published the 5th (pre final) release of the COVID-19 Recommendations and Guidelines – https://doi.org/10.15497/rda00046
This version is now open for public comment until 8 June 2020
I would ask you all to circulate this document and the executive summary and press release to your networks (links below). In addition to collecting feedback on this before it is officially endorsed, we want to broadcast far and wide this amazing community collaboration, cooperation and co creation for the benefit of the stakeholders.
Though our work is not done, this release is a significant milestone. It is a culmination of thousands and thousands of hours volunteer effort from experts across many disciplines. It is the fruit of an unbelievable drive and demonstration of passion and dedication from a global RDA community. A community I am so proud to represent.
I would like to thank you all so much for responding to the call for action less than 2 months ago. Please allow me to thank especially the co-chairs, moderators and the editorial team whose energy and tireless efforts have amazed and astounded me over this intense period.
My sincerest gratitude to you all
Hilary
News piece and press content at https://www.rd-alliance.org/global-research-data-alliance-community-resp
1. Research Data Alliance COVID-19 Recommendations and Guidelines Executive Summary
2. Research Data Alliance COVID-19 Complete Recommendations and Guidelines – 28 May 2020 Release
3. RDA COVID-19 Working Group
4. RDA COVID-19 All Working Group Outputs (5 releases)

Dr Anne Cambon-Thomsen
Directrice de recherche émérite au CNRS
UMR 1027, Inserm, Univ Toulouse III – Paul Sabatier http://www.u1027.inserm.fr
Plateforme sociétale genotoul http://societal.genotoul.fr/
Ambassador of the Research Data Alliance (RDA) for health sciences and research ethics http://www.rd-alliance.org
37 allées Jules Guesde F-31000 Toulouse
Tel : +33 (0)5 61 14 59 59 Mobile: +33 (0)6 79 41 13 48 Fax : +33 (0)5 61 14 56 23 Skype: act_pro
E-mail :

Homepage